Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates.
Journal Article (Journal Article)
The development of an effective AIDS vaccine remains a challenge. Nucleoside-modified mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of immunization against infectious diseases in preclinical studies, and are being tested for SARS-CoV-2 in humans. A critical question is how mRNA-LNP vaccine immunogenicity compares to that of traditional adjuvanted protein vaccines in primates. Here, we show that mRNA-LNP immunization compared to protein immunization elicits either the same or superior magnitude and breadth of HIV-1 Env-specific polyfunctional antibodies. Immunization with mRNA-LNP encoding Zika premembrane and envelope or HIV-1 Env gp160 induces durable neutralizing antibodies for at least 41 weeks. Doses of mRNA-LNP as low as 5 μg are immunogenic in macaques. Thus, mRNA-LNP can be used to rapidly generate single or multi-component vaccines, such as sequential vaccines needed to protect against HIV-1 infection. Such vaccines would be as or more immunogenic than adjuvanted recombinant protein vaccines in primates.
Full Text
Duke Authors
- Ferrari, Guido
- Haynes, Barton Ford
- Montefiori, David Charles
- Mu, Charlie
- Saunders, Kevin O'Neil
- Shen, Xiaoying
- Tomaras, Georgia Doris
Cited Authors
- Saunders, KO; Pardi, N; Parks, R; Santra, S; Mu, Z; Sutherland, L; Scearce, R; Barr, M; Eaton, A; Hernandez, G; Goodman, D; Hogan, MJ; Tombacz, I; Gordon, DN; Rountree, RW; Wang, Y; Lewis, MG; Pierson, TC; Barbosa, C; Tam, Y; Matyas, GR; Rao, M; Beck, Z; Shen, X; Ferrari, G; Tomaras, GD; Montefiori, DC; Weissman, D; Haynes, BF
Published Date
- April 9, 2021
Published In
Volume / Issue
- 6 / 1
Start / End Page
- 50 -
PubMed ID
- 33837212
Pubmed Central ID
- PMC8035178
Electronic International Standard Serial Number (EISSN)
- 2059-0105
Digital Object Identifier (DOI)
- 10.1038/s41541-021-00307-6
Language
- eng
Conference Location
- England